Targeted Maintenance Treatment in Schizophrenia: Issues and Recommendations

CNS Drugs

Volumn 5, Issue 4, 1996, Pages 240-245

  Buchanan, Robert W ^a   Carpenter Jr , William T ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

AGRANULOCYTOSIS; DRUG TARGETING; HUMAN; NEGATIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA; SEDATION; SHORT SURVEY; SIDE EFFECT; WEIGHT GAIN;

EID: 0029930020     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199605040-00002     Document Type: Review

References (17)

1. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993; 19 (2): 287-302
2. Goldberg E. Akinesia, tardive dysmentia and frontal lobe disorder in schizophrenia. Schizophr Bull 1985; 11 (2): 255-63
3. Jolley AG, Hirsch SR, McRink A, et al. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. BMJ 1989 Apr; 298: 985-90
4. Pietzcker A, Gaebel W, Kopcke W, et al. Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia - 2 year results of a German multicenter study. J Psychiatr Res 1993; 27 (4): 321-39
5. Carpenter Jr WT, Heinrichs DW. Early intervention, time-limited, targeted pharmacotherapy of schizophrenia. Schizophr Bull 1983; 9 (4): 533-42
6. Herz MI, Glazer WM, Mostert MA, et al. Intermittent vs. maintenance medication in schizophrenia. Arch Gen Psychiatry 1991 Apr; 49: 333-9
7. Bustillo J, Buchanan RW, Carpenter Jr WT. Prodromal symptoms vs early warning signs and clinical action in schizophrenia. Schizophr Bull 1995; 21 (4): 553-60
8. Norman RMG, Malla AK. Prodromal symptoms of relapse in schizophrenia: a review. Schizophr Bull 1995; 21 (4): 527-40
9. Carpenter WT, Heinrichs DW, Hanlon TE. A comparative trial of pharmacologic strategies in schizophrenia. Am J Psychiatry 1987 Nov; 144 (11): 1466-70
10. Carpenter Jr WT, Hanlon TE, Heinrichs DW, et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990 Sept; 147 (9): 1138-48
11. Jolley AB, Hirsch SR, Morrison E. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ 1990 Oct; 301: 837-42
12. Schooler NR. Integration of family and drug treatment strategies in the treatment of schizophrenia: a selective review. Int Clin Psychopharmacol. In press
13. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-96
14. Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151: 20-6
15. Zito JM, Volavka J, Craig TJ, et al. Pharmacoepidemiology of clozapine in 202 inpatients with schizophrenia. Ann Pharmacother 1993; 27: 1262-9
16. Buchanan RW. Clozapine: efficacy and safety. Schizophr Bull 1995; 21 (4): 579-92
17. Herz MI, Szymanski HV, Simon JC. Intermittent medication for stable schizophrenic outpatients: an alternative to maintenance medication. Am J Psychiatry 1982 Jul; 139 (7): 918-22